Personalised medicine: What is personalised medicine?

David Champeaux is a digital entrepreneur and advisor to health systems and health technology innovators, focused on transforming health and care delivery and payment models, sustainably and at scale. His digital entrepreneurship experience, gained across multiple industries ranging from the global logistics industry to SaaS for enterprise mobility, has focused on designing innovation into the lives of people - both customers and service providers - and into the commercial, regulatory and process fabric of complex networked ecosystems. As a Partner at McKinsey and then Accenture, and later as healthcare business lead for IPsoft, a cognitive AI platform provider, David translated these insights into healthcare ecosystems across the world, from the UK and Europe to Singapore and Australia, working with payors and providers, and innovators from within the health ecosystem as well as new entrants, on designing and driving sustainable adoption of digital-enabled innovations, at scale. 

David Champeaux is now the Chief Growth Officer for Cherish Health, where he is leading its international development, as well as engagement with relevant ecosystem partners who extend and complement Cherish Health’s solutions with relevant content, services and products. David also serves on the Advisory Council for HIMSS in Europe, is a non-executive board member for LiveBetterWith, a UK healthcare community helping people cope with specific chronic conditions, and is a Healthcare Affiliate Partner for IPsoft, advising on the development of AI-enabled conversational agents in health and care.

Professor Bill Newman is a clinician scientist. He studied Medicine at Manchester University and completed professional training in adult medicine in the North West of England. He started training in Clinical Genetics in 1995 and undertook a PhD as a Wellcome Trust Clinical Training Fellow on the genetics of bone development and osteoarthritis in the Wellcome Trust Cell Matrix Centre. He moved to Toronto to undertake a two-year Arthritis Society Fellowship with Professor Kathy Siminovitch where he worked on the genetic basis of rheumatoid arthritis and inflammatory bowel disease.

Professor Newman took up his post as Clinical Senior Lecturer in Genetics at the University of Manchester and Honorary Consultant at St Mary's Hospital in 2004 and was awarded Chair in 2013. His research focuses on pharmacogenetics - defining the genetic factors that influence how patients respond to their medications. He has an interest in rare diseases and has discovered a number of genes responsible for a range of conditions and complex mutational mechanisms that lead to these.

Glen de Vries is co-CEO and co-founder of Medidata, the most-used platform for clinical trials around the world. Medidata has powered tens of thousands of clinical trials, with millions of patients and billions of patient records. In 2019, in one of the largest health care technology acquisitions in history, Medidata became part of Dassault Systèmes. Glen has been driving Medidata’s mission since the company’s inception in 1999, “powering smarter treatments and healthier people” by advancing pharmaceutical business transformation with technology, non-traditional ways of thinking, and industry collaboration. Glen’s publications have appeared in Applied Clinical Trials, Cancer, The Journal of Urology, Molecular Diagnostics, and other journals. He serves as a trustee of Carnegie Mellon University and is the author of The Patient Equation (de Vries & Blachman, 2020).

Glen received his undergraduate degree in molecular biology and genetics from Carnegie Mellon University, worked as a research scientist at the Columbia Presbyterian Medical Center and studied computer science at New York University's Courant Institute of Mathematics.